On the Record · West Pharmaceutical Services
West Pharmaceutical Services acquisitions, on the record
The businesses West Pharmaceutical Services bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
DaikyoWord for word“Additionally, during 2023, 2022 and 2021, the company recorded $2.1 million of amortization expense in association with an acquisition of increased ownership interest in Daikyo.” 10-K for 2023 | acquisition | — | — |
Acquisition of business (cash flow line, 2021)Word for word“Acquisition of business — — ( 2.2 ) ” 10-K for 2023 | acquisition | — | ( 2.2 ) |
one of the Company’s manufacturing facilities within the Proprietary Products segmentWord for word“(3) During 2023 , the Company recorded expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment.” 10-K for 2024 | divestiture | During 2023 | — |
SmartDose® 3.5mL On-Body Delivery System manufacturing and supply rights and associated facilities (to AbbVie)Word for word“As a recent example, the Company entered into a definitive agreement to sell all manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie.” 10-K for 2025 | agreed divestiture | — | — |
| Fiscal year ended | Goodwill from acquisitions |
|---|---|
| 2019-12-31 | $2.6 million |
| 2021-12-31 | $1.7 million |
Deal filings since 2016
- 2026-07-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-11-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-04-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-04-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from West Pharmaceutical Services’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.